Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors	Solid Cancers	Recruiting	Phase 2	2025-09-12		NCT07170293

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tianjin Medical University Second Hospital	50

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Tianjin Medical Unversity Second Hospital	Tianjin	China	6

Clinical trials